174 related articles for article (PubMed ID: 21828236)
21. Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality.
Rai M; Parthasarathi A; Beeraka NM; Kaleem Ullah M; Malamardi S; Padukudru S; Siddaiah JB; Uthaiah CA; Vishwanath P; Chaya SK; Ramaswamy S; Upadhyay S; Ganguly K; Mahesh PA
Cells; 2023 Apr; 12(9):. PubMed ID: 37174681
[TBL] [Abstract][Full Text] [Related]
22. Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features.
Xue M; Cai C; Zeng Y; Xu Y; Chen H; Hu H; Zhou L; Sun B
Medicine (Baltimore); 2021 Jan; 100(4):e24260. PubMed ID: 33530214
[TBL] [Abstract][Full Text] [Related]
23. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
[TBL] [Abstract][Full Text] [Related]
25. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
[TBL] [Abstract][Full Text] [Related]
26. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.
Ohnishi H; Yokoyama A; Kondo K; Hamada H; Abe M; Nishimura K; Hiwada K; Kohno N
Am J Respir Crit Care Med; 2002 Feb; 165(3):378-81. PubMed ID: 11818324
[TBL] [Abstract][Full Text] [Related]
28. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.
Katseli A; Maragos H; Nezos A; Syrigos K; Koutsilieris M
Clin Lung Cancer; 2013 Sep; 14(5):513-20. PubMed ID: 23810363
[TBL] [Abstract][Full Text] [Related]
29. Impact of anti-tumor necrosis factor-α agents on serum levels of KL-6 and surfactant protein-D in patients with psoriasis.
Hayashi M; Yanaba K; Umezawa Y; Asahina A; Nakagawa H
J Dermatol; 2017 Sep; 44(9):1063-1066. PubMed ID: 28370220
[TBL] [Abstract][Full Text] [Related]
30. Usefulness and performance evaluation of serum KL-6 and SP-A assays in healthy individuals and patients with interstitial lung disease.
Cho EJ; Hong J; Hyun J; Lee W; Kim HS; Chun S; Min WK
Clin Biochem; 2023 Aug; 118():110609. PubMed ID: 37414329
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
32. Analysis of KL-6 and SP-D as disease markers in bird fancier's lung.
Janssen R; Grutters JC; Sato H; van Velzen-Blad H; Zanen P; Kohno N; Welsh KI; du Bois RM; van den Bosch JM
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Mar; 22(1):51-7. PubMed ID: 15881280
[TBL] [Abstract][Full Text] [Related]
33. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
34. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
35. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
36. No association between circulating concentrations of vitamin D and risk of lung cancer: an analysis in 20 prospective studies in the Lung Cancer Cohort Consortium (LC3).
Muller DC; Hodge AM; Fanidi A; Albanes D; Mai XM; Shu XO; Weinstein SJ; Larose TL; Zhang X; Han J; Stampfer MJ; Smith-Warner SA; Ma J; Gaziano JM; Sesso HD; Stevens VL; McCullough ML; Layne TM; Prentice R; Pettinger M; Thomson CA; Zheng W; Gao YT; Rothman N; Xiang YB; Cai H; Wang R; Yuan JM; Koh WP; Butler LM; Cai Q; Blot WJ; Wu J; Ueland PM; Midttun Ø; Langhammer A; Hveem K; Johansson M; Hultdin J; Grankvist K; Arslan AA; Le Marchand L; Severi G; Johansson M; Brennan P
Ann Oncol; 2018 Jun; 29(6):1468-1475. PubMed ID: 29617726
[TBL] [Abstract][Full Text] [Related]
37. Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan.
Huang H; Peng X; Nakajima J
Biosci Trends; 2013 Aug; 7(4):172-7. PubMed ID: 24056167
[TBL] [Abstract][Full Text] [Related]
38. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
39. The Serum Level of KL-6 Is Associated with the Risk of Insulin Resistance and New-onset Diabetes Mellitus: The Tanno-Sobetsu Study.
Akasaka H; Ohnishi H; Narita Y; Kameda M; Miki T; Takahashi H; Yamamoto W; Sohma H; Masumori N; Miura T;
Intern Med; 2017 Nov; 56(22):3009-3018. PubMed ID: 28943558
[TBL] [Abstract][Full Text] [Related]
40. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy.
Yamashita H; Kobayashi-Shibata S; Terahara A; Okuma K; Haga A; Wakui R; Ohtomo K; Nakagawa K
Radiat Oncol; 2010 May; 5():32. PubMed ID: 20459699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
